«上一篇/Previous Article|本期目录/Table of Contents|下一篇/Next Article»

《中华肺部疾病杂志》[ISSN:1006-6977/CN:61-1281/TN]

卷:

期数:

2025年01期

页码:

86-91

栏目:

论著

出版日期:

2025-02-25

文章信息/Info

Title:

Analysis of adverse reactions of eosinophilia in perinatal women with pulmonary embolism induced by nadroparin

作者:

冯 强¹; 童姗姗²; 吴学玲³; 崔 敏⁴

361101 厦门,厦门市第五医院药剂科¹
200065 上海,同济大学附属同济医院药剂科²
200127 上海,上海交通大学医学院附属仁济医院呼吸科³
200127 上海,上海交通大学医学院附属仁济医院药剂科⁴

Author(s):

Feng Qiang¹;  Tong Shanshan²;  Wu Xueling³;  Cui Min⁴.

¹Pharmacy Department, The Fifth Hospital of Xiamen, Xiamen 361101, China; ²Pharmacy Department, Tongji Hospital, School of Medicine, Tongji University, Shanghai 200065, China; ³Respiratory Department, Shanghai Jiaotong Uni

关键词:

肺栓塞;  嗜酸性粒细胞增多;  那曲肝素;  围产期;  不良反应;  临床特点

Keywords:

Pulmonary embolism;  Eosinophilia;  Nadroparin;  Perinatal women;  Adverse reactions;  Clinical characteristics

分类号:

R563

DOI:

10.3877/cma.j.issn.1674-6902.2025.01.014

摘要:

目的 探索围产期肺栓塞(pulmonary embolism, PE)患者使用那曲肝素(nadroparin calcium, NC)引起嗜酸性粒细胞(eosinophil, Eos)增多不良反应的临床特点,为临床用药安全提供参考依据。方法 选择2020年1月至2023年12月我院收治的肺栓塞的围产期患者在使用那曲肝素治疗过程中出现嗜酸粒细胞增多的病例,提取患者基本信息,包括年龄、体重、基础疾病、诊断肺栓塞时机、那曲肝素用法用量、合并用药、嗜酸粒细胞计数基线值、嗜酸粒细胞增多发生时间、嗜酸粒细胞计数峰值、是否伴随皮肤症状、嗜酸粒细胞计数恢复至正常值时间及不良反应转归。结果 共有8例围产期肺栓塞患者在使用那曲肝素过程中出现嗜酸粒细胞增多的不良反应。患者年龄介于27～34岁之间,在确诊肺栓塞后予那曲肝素规范化治疗,无其他合并用药。监测到嗜酸粒细胞增多发生时间最早为用药后的12 d,该患者嗜酸粒细胞计数基础值(0.26×10⁹/L)较其他患者稍高; 嗜酸粒细胞增多发生时间最迟为用药后的70 d,该患者不良反应最轻微,其嗜酸粒细胞计数峰值为0.55×10⁹/L。1例患者达到嗜酸粒细胞重度增多临床诊断,其嗜酸粒细胞计数峰值为5.31×10⁹/L。3例患者伴随皮肤症状,停药后症状消失。7例患者在出现嗜酸粒细胞增多后予减量/停药/抗凝方案的调整,停药后2～114 d嗜酸粒细胞计数恢复至正常水平,未予其他干预措施,其中减量处理的患者监测其嗜酸粒细胞计数持续增多,后予停药处理后好转。1例患者在出现嗜酸粒细胞增多后未调整治疗方案,其嗜酸粒细胞持续升高,后失去随访资料。结论 围产期肺栓塞患者使用那曲肝素致嗜酸粒细胞增多发生时间一般在用药后的10周内,部分患者伴随皮肤症状如皮肤瘙痒等,停药后可恢复。临床在使用那曲肝素治疗围产期肺栓塞患者时,应密切关注嗜酸粒细胞计数变化,以便及时发现并妥善处理这一不良反应,保障患者的用药安全和治疗效果。

Abstract:

Objective To explore the clinical characteristics of nadroparin-induced eosinophilia in perinatal women with pulmonary embolism and provide a reference for clinical drug safety. Methods Cases of perinatal patients diagnosed with pulmonary embolism who developed eosinophilia during treatment with nadroparin between 2020-2023 were collected. Basic patient information was extracted, including age, body weight, underlying disease, pulmonary embolism diagnosis timing, nadroparin dosage, comorbidities, baseline eosinophil count, time to onset of eosinophilia, peak eosinophil count, presence of skin symptoms, time for eosinophil count to return to normal level, and regression of adverse effects. Results A total of 8 perinatal women with pulmonary embolism experienced eosinophilia during the administration of nadroparin. The patients were aged 27 to 34 years and all were treated with nadroparin after diagnosis of pulmonary embolism without other concomitant medications. Eosinophilia was detected as early as 12 days post-dose, with a slightly higher basal eosinophil count(0.26×10⁹/L)than the other patients. Eosinophilia was detected as late as 70 days post-dose, and this patient had the mildest adverse effect with a peak eosinophil count of 0.55×10⁹/L). One patient reached the clinical diagnosis of severe eosinophilia with a peak eosinophil count of 5.31×10⁹/L. Three patients had accompanying skin symptoms, which disappeared after discontinuation of the drug. Seven patients had their dosage reduced, discontinued the drug, or changed their anticoagulation regimen after the eosinophil count increased. The eosinophil count returned to normal levels 2-114 days after drug withdrawal without other intervention measures. Among them, the eosinophil count of patients treated with reduced dosage continued to increase and then improved after drug withdrawal. Another patient did not adjust the treatment plan, and her eosinophils continued to rise, subsequent follow-up data were lost. Conclusion Nadroparin-induced eosinophilia in perinatal women with pulmonary embolism occurs within 10 weeks, and some patients may experience skin symptoms such as itchiness, which generally recover after drug discontinuation. When using nadroparin to treat perinatal patients with pulmonary embolism, clinicians should closely monitor eosinophil count changes to promptly detect and appropriately manage this adverse reaction.

参考文献/References:

1 张 川, 张 力, 李泳琴, 等. 低分子肝素用于妊娠期安全性的系统评价[J]. 中国循证医学杂志, 2021, 21(11): 1259-1268.
2 Greer IA. Thrombosis in pregnancy: Maternal and fetal issues[J]. Lancet, 1999, 353(9160): 1258-1265.
3 Martel N, Lee J, Wells PS. Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis[J]. Blood, 2005, 106(8): 2710-2705.
4 McGowan KE, Makari J, Diamantouros A, et al. Reducing the hospital burden of heparin-induced thrombocytopenia: impact of an avoid-heparin program[J]. Blood, 2016, 127(16): 1954-1959.
5 Forestier F, Daffos F, Capella-Pavlovsky M. Low molecular weight heparin(PK 10169)does not cross the placenta during the second trimester of pregnancy study by direct fetal blood sampling under ultrasound[J]. Thromb Res, 1984, 34(6): 557-560.
6 Forestier F, Daffos F, Rainaut M, et al. Low molecular weight heparin(CY 216)does not cross the placenta during the third trimester of pregnancy[J]. Thromb Haemost, 1987, 57(2): 234.
7 中华医学会呼吸病学分会肺栓塞与肺血管病学组, 中国医师协会呼吸医师分会肺栓塞与肺血管病工作委员会, 全国肺栓塞与肺血管病防治协作组. 肺血栓栓塞症诊治与预防指南[J]. 中华医学杂志, 2018, 98(14): 1060-1087.
8 Bates SM, Rajasekhar A, Middeldorp S, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: Venous thromboembolism in the context of pregnancy[J]. Blood Adv, 2018, 2(22): 3317-3359.
9 Ensom MH, Stephenson MD. Pharmacokinetics of low molecular weight heparin and unfractionated heparin in pregnancy[J]. J Soc Gynecol Investig, 2004, 11(6): 377-383.
10 Sirico A, Saccone G, Maruotti GM, et al. Low molecular weight heparin use during pregnancy and risk of postpartum hemorrhage: a systematic review and meta-analysis[J]. J Matern Fetal Neonatal Med, 2019, 32(11): 1893-1900.
11 Schindewolf M, Lindhoff-Last E, Ludwig RJ, et al. Heparin-induced skin lesions[J]. Lancet, 2012, 380(9856):1867-1879.
12 Klion AD, Ackerman SJ, Bochner BS. Contributions of eosinophils to human health and disease[J]. Annu Rev Pathol, 2020, 15:179-209.
13 Wen T, Rothenberg ME. The regulatory function of eosinophils[J]. Microbiology Spectrum, 2016, 4(5):10.1128/microbiolspec.MCHD-0020-2015.
14 Kato M, Kephart GM, Talley NJ, et al. Eosinophil infiltration and degranulation in normal human tissue[J]. Anat Rec, 1998, 252(3):418-425.
15 Masterson JC, Menard-Katcher C, Larsen LD, et al. Heterogeneity of intestinal tissue eosinophils: Potential considerations for next-generation eosinophil-targeting strategies[J]. Cells, 2021, 10(2):426.
16 Constantine GM, Klion AD. Recent advances in understanding the role of eosinophils[J]. Fac Rev, 2022, 11:26.
17 Leiferman KM, Ackerman SJ, Sampson HA, et al. Dermal deposition of eosinophil-granule major basic protein in atopic dermatitis. Comparison with onchocerciasis[J]. N Engl J Med, 1985, 313(5): 282-285.
18 Makiya MA, Herrick JA, Khoury P, et al. Development of a suspension array assay in multiplex for the simultaneous measurement of serum levels of four eosinophil granule proteins[J]. J Immunol Methods, 2014, 411: 11-22.
19 Mejia R, Nutman TB. Evaluation and differential diagnosis of marked, persistent eosinophilia[J]. Semin Hematol, 2012, 49(2): 149-159.
20 Chen T, Lan L, Sun W, et al. Localized and Generalized Skin Adverse Drug Reactions to Nadroparin Calcium Injection in 6 Cases of Pregnant Women[J]. J Healthc Eng, 2022, 2022: 5622482.
21 郎 奕. 药物引起的嗜酸性粒细胞增多[J]. 天津药学, 2003, 15(1): 66-69.
22 Bircher AJ, Harr T, Hohenstein L, Tsakiris DA. Hypersensitivity reactions to anticoagulant drugs: diagnosis and management options[J]. Allergy, 2006, 61(12): 1432-1440.
23 Klos K, Spiewak R, Kruszewski J, Bant A. Cutaneous adverse drug reaction to heparins with hypereosinophilia and high IgE level[J]. Contact Dermatitis, 2011, 64(1): 61-62.
24 陈灏珠. 实用内科学[M]. 15版. 北京: 人民卫生出版社, 2017: 1787-1790.
25 中华医学会血液学分会白血病淋巴瘤学组.中国嗜酸性粒细胞增多症诊断和治疗指南(2024版)[J].中华血液学杂志, 2024, 45(1):1-7.
26 Funck-Brentano E, Duong TA, Bouvresse S, et al. Therapeutic management of DRESS: A retrospective study of 38 cases[J]. J Am Acad Dermatol, 2015, 72(2):246-252.
27 Uhara H, Saiki M, Kawachi S, et al. Clinical course of drug-induced hypersensitivity syndrome treated without systemic corticosteroids[J]. J Eur Acad Dermatol Venereol, 2013, 27(6):722-726.
28 汤 蕊, 陈 适, 张宏誉. 阿托伐他汀引起嗜酸性粒细胞增多1例[J]. 中华临床免疫和变态反应杂志, 2014, 8(2):161-162.
29 Shiohara T, Kano Y. Drug reaction with eosinophilia and systemic symptoms(DRESS): Incidence, pathogenesis and management[J]. Expert Opin Drug Saf, 2017, 16(2):139-147.
30 Natkunarajah J, Goolamali S, Craythorne E, et al. Ten cases of drug reaction with eosinophilia and systemic symptoms(DRESS)treated with pulsed intravenous methylprednisolone[J]. Eur J Dermatol, 2011, 21(3): 385-391.
31 Roujeau JC, Haddad C, Paulmann M, et al. Management of nonimmediate hypersensitivity reactions to drugs[J]. Immunol Allergy Clin North Am, 2014, 34(3):473-487.
32 武玉霞, 单 丹, 陈 倩, 等. 妊娠期肺血栓栓塞症的临床诊治进展[J]. 实用妇产科杂志, 2021, 37(5): 348-353.
33 Lowe SA, Barrett HL, Cutts BA, et al. Update on pulmonary embolism in pregnancy and post-partum: the society of obstetric medicine of australia and new zealand position statement on pulmonary embolism in pregnancy and post-partum[J]. Aust N Z J Obstet Gynaecol, 2021, 61(6): 830-836.
34 Vu TT, Gooderham M. Adverse drug reactions and cutaneous manifestations associated with anticoagulation[J]. J Cutan Med Surg, 2017, 21(6): 540-550.

备注/Memo

备注/Memo:

通信作者: 崔 敏, Email: 13816752601@163.com

常用功能

更新日期/Last Update: 2025-02-20